Johnson & Johnson (NYSE: JNJ) has raised its dividend for 64 consecutive years, cementing its place among the most reliable income stocks in the market.
Only eight other Dividend Kings, companies that have raised dividends for at least 50 straight years, can claim a longer streak of uninterrupted annual dividend growth.
The pharmaceutical giant is not resting on its income credentials, having shifted significantly toward growth since making oncology a strategic priority in 2024.
A string of acquisitions including Shockwave Medical, Intra-Cellular Therapies, Halda Therapeutics, and most recently Firefly Bio has transformed J&J into a more dynamic investment proposition.
The company is targeting annual oncology drug sales of $50 billion by 2030, positioning itself as the largest name in the cancer treatment business.
That growth ambition has been reflected in the share price, which has gained nearly 80% since the end of 2024, a performance more typical of a growth stock than a traditional income play.
For investors focused on dividend income, a $10,000 position in J&J currently represents around 39 shares at prevailing prices.
With a forward-looking dividend yield of approximately 2.1%, that holding would generate close to $210 in annual dividend income.
J&J’s dividend growth over the past decade has been steady rather than spectacular, improving by 67% over ten years for an average annual increase of about 5.3%.
While higher-yielding alternatives exist in the market, few companies can match the consistency and longevity of J&J’s dividend track record, which is underpinned by a constantly evolving pharmaceutical pipeline.
Pharmaceutical companies naturally face headwinds from patent expirations, but J&J’s aggressive dealmaking strategy has given it a robust path to sustained revenue growth well beyond its current portfolio.
Income-focused investors willing to accept a modest yield in exchange for long-term reliability and growing capital appreciation potential may find J&J a compelling fit in a diversified portfolio.
